Aspirin-Exacerbated Respiratory Disease and the Role of Type 2 Inflammation (AAN)
Price: FREE for members and non-members
Session recorded on September 26, 2023
Speaker: Rajan Merchant, MD, FACAAI
People with AERD live with asthma, sinus disease and recurrent nasal polyps, and are sensitive to aspirin and other non-steroidal anti-inflammatory drugs (NSAIDS). Many are undiagnosed. In this activity, Dr. Rajan Merchant will review the history and clinical features of AERD, type II inflammation and treatment options for those living with this challenging condition.
Viewers can earn credit by completing the post-test questions.
This program is a collaboration between the American College of Allergy, Asthma & Immunology and the Allergy and Asthma Network (AAN).
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Primary Care Providers
Allied Health Professionals
Upon completion of this activity learners should be able to
1. Identify the clinical features of AERD.
2. Describe type 2 inflammation.
3. Explain the treatment options for AERD.
Disclosure Policy and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewer, and other individuals in a position to control or influence the content of an activity must disclose ALL financial relationships with any ineligible company. The ACCME defines an “ineligible company” (formerly commercial interest) as a company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. (Examples of ineligible companies include: Advertising, marketing, or communication firms whose clients are ineligible companies; bio-medical startups that have begun a governmental regulatory approval process; compounding pharmacies that manufacture proprietary compounds; device manufacturers or distributors; diagnostic labs that sell proprietary products; growers, distributors, manufacturers or sellers of medical foods and dietary supplements; manufacturers of health-related wearable products; pharmaceutical companies or distributors; pharmacy benefit managers; reagent manufacturers or sellers). For more information, visit www.accme.org.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.
All identified relevant financial relationships with ineligible companies have been mitigated.
Rajan Merchant, MD, FACAAI, Speaker
Advisor: Teva, ResMed
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance